

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450  
Alexandria, VA 22313 on August 28, 2006

*Frank C. Eisenschenk*  
Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE  
STATEMENT  
Examining Group 1644  
Patent Application  
Docket No. ARS-120  
Serial No. 10/565,741

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1644  
Applicant : Yolande Chvatchko  
Serial No. : 10/565,741  
Filed : January 23, 2006  
Conf. No. : 2192  
For : Use of Soluble CD164 in Inflammatory and/or Autoimmune Disorders

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 U.S.C. § 371. Applicant has been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notice of Acceptance of the Application Under 35 USC 371 (Form PCT/DO/EO/903). The Notice does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience. In accordance with 37 C.F.R. § 1.56, Applicant hereby requests that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

Applicant has also listed on form PTO/SB/08 numerous references which have not been cited in the International Search Report. Copies of these documents are enclosed with this Information

Disclosure Statement. Applicant respectfully requests that these references be made of record and considered in the examination of the subject application.

Applicant respectfully asserts that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,



Frank C. Eisenschenk, Ph.D.  
Patent Attorney  
Registration No. 45,332  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of cited references.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/565,741
Sheet	1	of	6	Filing Date	January 23, 2006
				First Named Inventor	Yolande Chvatchko
				Art Unit	1644
				Examiner Name	
				Attorney Docket Number	ARS-120

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
	F1	WO 02/098917 A2 (CD-ROM)	12-12-2002	Curagen Corporation	All
	F2	EP 1033401 A2 (CD-ROM)	09-06-2000	Genset	All
	F3				
	F4				
	F5				
	F6				
	F7				

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	2	of	6	Application Number	10/565,741
				Filing Date	January 23, 2006
				First Named Inventor	Yolande Chvatchko
				Group Art Unit	1644
				Examiner Name	
				Attorney Docket Number	ARS-120

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	ALTSCHUL, S.F. et al. "Basic Local Alignment Search Tool," <i>J. Mol. Biol.</i> , 1990, pp. 403-410, Vol. 215.	
	R2	ALTSCHUL, S.F. et al. "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," <i>Nucleic Acids Research</i> , 1997, pp. 3389-3402, Vol. 25, No. 17.	
	R3	ANTHONY-CAHILL, S.J. and MAGLIERI, T.J. "Expanding the Natural Repertoire of Protein Structure and Function," <i>Current Pharmaceutical Biotechnology</i> , 2002, pp. 299-315, Vol. 3.	
	R4	ARMALEO, D. et al. "Biostatic nuclear transformation of <i>Saccharomyces cerevisiae</i> and other fungi," <i>Curr Genet</i> , 1990, pp. 97-103, Vol. 17.	
	R5	BROWN, A.R. et al. "The Total Chemical Synthesis of Monocyte Chemotactic Protein-1 (MCP-1)," <i>Journal of Peptide Science</i> , 1996, pp. 40-46, Vol. 2.	
	R6	BRUTLAG, D.L. et al. "Improved sensitivity of biological sequence database searches," <i>Comput Appl Biosci</i> , 1990, pp. 237-245, Vol. 6, No. 3.	
	R7	CASI, G. and HILVERT, D. "Convergent protein synthesis," <i>Current Opinion in Structural Biology</i> , 2003, pp. 589-594, Vol. 13.	
	R8	CHAI, H. et al. "Glycosylation and high-level secretion of human tumour necrosis factor- $\beta$ in recombinant baculovirus-infected insect cells," <i>Biotechnol. Appl. Biochem.</i> , 1993, pp. 259-273, Vol. 18.	
	R9	CHAN, J.Y.-H. et al. "Relationship between Novel Isoforms, Functionally Important Domains, and Subcellular Distribution of CD164/Endolyn," <i>The Journal of Biological Chemistry</i> , January 19, 2001, pp. 2139-2152, Vol. 276, No. 3.	
	R10	CLARK, A.J. "The Mammary Gland as a Bioreactor: Expression, Processing, and Production of Recombinant Proteins," <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1998, pp. 337-350, Vol. 3, No. 3.	
	R11	CLELAND, J.L. "The Development of Stable Protein Formulations: A Close Look at Protein Aggregation, Deamidation, and Oxidation," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 1993, pp. 307-377, Vol. 10, No. 4.	
	R12	CLELAND, J.L. "Emerging protein delivery methods," <i>Current Opinion in Biotechnology</i> , 2001, pp. 212-219, Vol. 12.	
	R13	CUNNINGHAM, B.C. and WELLS, J.A. "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis," <i>Science</i> , June 2, 1989, pp. 1081-1085, Vol. 244.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	3	of	6	Application Number	10/565,741
				Filing Date	January 23, 2006
				First Named Inventor	Yolande Chvatchko
				Group Art Unit	1644
				Examiner Name	
				Attorney Docket Number	ARS-120

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	R14	DOUGHERTY, D.A. "Unnatural amino acids as probes of protein structure and function," <i>Current Opinion in Chemical Biology</i> , 2000, pp. 645-652, Vol. 4.			
	R15	DOYONNAS, R. et al. "CD164 Monoclonal Antibodies That Block Hemopoietic Progenitor Cell Adhesion and Proliferation Interact with the First Mucin Domain of the CD164 Receptor," <i>The Journal of Immunology</i> , 2000, pp. 840-851, Vol. 165.			
	R16	FELDMAN, L.J. "Adenovirus-mediated arterial gene therapy for restenosis: problems and perspectives," <i>Semin Intervent Cardiol</i> , 1996, pp. 203-208, Vol. 1.			
	R17	GENDEL, S.M. "Sequence Analysis for Assessing Potential Allergenicity," <i>Annals New York Academy of Sciences</i> , 2002, pp. 87-98, Vol. 964.			
	R18	GENTZ, R. et al. "Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: Trans-activation requires mRNA synthesis," <i>Proc. Natl. Acad. Sci. USA</i> , February 1989, pp. 821-824, Vol. 86.			
	R19	GISH, W. and STATES, D.J. "Identification of protein coding regions by database similarity search," <i>Nature Genetics</i> , March 1993, pp. 266-272, Vol. 3.			
	R20	GOLEBIOWSKI, A. et al. "High-throughput organic synthesis of peptide mimetics," <i>Current Opinion in Drug Discovery and Development</i> , 2001, pp. 428-434, Vol. 4, No. 4.			
	R21	GONNET, G.H. et al. "Exhaustive Matching of the Entire Protein Sequence Database," <i>Science</i> , June 5, 1992, pp. 1443-1445, Vol. 256.			
	R22	GOR, D.O. et al. "T <sub>H</sub> 1-T <sub>H</sub> 2: a Procrustean paradigm," <i>Nature Immunology</i> , June 2003, pp. 503-505, Vol. 4, No. 6.			
	R23	GRADDIS, T.J. et al. "Designing Proteins That Work Using Recombinant Technologies," <i>Current Pharmaceutical Biotechnology</i> , 2002, pp. 285-297, Vol. 3.			
	R24	GUSTAFSSON, C. et al. "Codon bias and heterologous protein expression," <i>TRENDS in Biotechnology</i> , July 2004, pp. 346-353, Vol. 22, No. 7.			
	R25	HENIKOFF, S. and HENIKOFF, J.G. "Performance Evaluation of Amino Acid Substitution Matrices," <i>PROTEINS: Structure, Function, and Genetics</i> , 1993, pp. 49-61, Vol. 17.			
	R26	HERRICK, C.A. and BOTTOMLY, K. "To Respond or Not to Respond: T Cells in Allergic Asthma," <i>Nat Rev Immunol</i> , May 2003, pp. 405-412, Vol. 3.			

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	4	of	6	Application Number	10/565,741
				Filing Date	January 23, 2006
				First Named Inventor	Yolande Chvatchko
				Group Art Unit	1644
				Examiner Name	
				Attorney Docket Number	ARS-120

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	R27	HIGGINS, D.G. <i>et al.</i> "Using CLUSTAL for Multiple Sequence Alignments," <i>Methods in Enzymology</i> , 1996, pp. 383-402, Vol. 266.			T <sup>2</sup>
	R28	HRUBY, V.J. and BALSE, P.M. "Conformational and Topographical Considerations in Designing Agonist Peptidomimetics from Peptide Leads," <i>Current Medicinal Chemistry</i> , 2000, pp. 945-970, Vol. 7.			
	R29	KARLIN, S. and ALTSCHUL, S.F. "Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes," <i>Proc Natl Acad Sci USA</i> , March 1990, pp. 2264-2268, Vol. 87.			
	R30	LEE, Y.-N. <i>et al.</i> "Identification of a Role for the Sialomucin CD164 in Myogenic Differentiation by Signal Sequence Trapping in Yeast," <i>Molecular and Cellular Biology</i> , November 2001, pp. 7696-7706, Vol. 21, No. 22.			
	R31	LENHARD, T. <i>et al.</i> "A new set of versatile vectors for the heterologous expression of foreign genes using the baculovirus system," <i>Gene</i> , 1996, pp. 187-190, Vol. 169.			
	R32	LUO, Y. and PRESTWICH, G. "Novel biomaterials for drug delivery," <i>Expert Opin. Ther. Patents</i> , 2001, pp. 1395-1410, Vol. 11, No. 9.			
	R33	MALIK, F. <i>et al.</i> "Polyethylene Glycol (PEG)-modified Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) with Conserved Biological Activity," <i>Exp. Hematol.</i> , 1992, pp. 1028-1035, Vol. 20.			
	R34	MARSHALL, S.A. <i>et al.</i> "Rational design and engineering of therapeutic proteins," <i>Drug Discov Today</i> , March 2003, pp. 212-221, Vol. 8, No. 5.			
	R35	MATSUI, T. <i>et al.</i> "The Ratio of Splicing Variants of MGC-24/CD164, a Sialomucin, Correlates with the Metastatic Potential of Colorectal Carcinomas," <i>J. Biochem</i> , 2000, pp. 1103-1107, Vol. 127, No. 6.			
	R36	MUIR, T.W. "Semisynthesis of Proteins by Expressed Protein Ligation," <i>Annu. Rev. Biochem.</i> , 2003, pp. 249-289, Vol. 72.			
	R37	MURPHY, L.R. <i>et al.</i> "Simplified amino acid alphabets for protein fold recognition and implications for folding," <i>Protein Engineering</i> , 2000, pp. 149-152, Vol. 13, No. 3.			
	R38	NICOLAU, C. <i>et al.</i> "Liposomes as Carriers for <i>in Vivo</i> Gene Transfer and Expression," <i>Methods in Enzymology</i> , 1987, pp. 157-176, Vol. 149.			
	R39	OHNO, T. <i>et al.</i> "Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial Injury," <i>Science</i> , August 5, 1994, pp. 781-784, Vol. 265.			

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	5	of	6	Application Number	10/565,741
				Filing Date	January 23, 2006
				First Named Inventor	Yolande Chvatchko
				Group Art Unit	1644
				Examiner Name	
				Attorney Docket Number	ARS-120

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	R40	PEARSON, W.R. and LIPMAN, D.J. "Improved tools for biological sequence comparison," <i>Proc Natl Acad Sci USA</i> , April 1988, pp. 2444-2448, Vol. 85.			T <sup>2</sup>
	R41	PILLAI, O. and PANCHAGNULA, R. "Polymers in drug delivery," <i>Current Opinion in Chemical Biology</i> , 2001, pp. 447-451, Vol. 5.			
	R42	ROGOV, S.I. and NEKRASOV, A.N. "A numerical measure of amino acid residues similarity based on the analysis of their surroundings in natural protein sequences," <i>Protein Engineering</i> , 2001, pp. 459-463, Vol. 14, No. 7.			
	R43	SCHELLEKENS, H. "Bioequivalence and the Immunogenicity of Biopharmaceuticals," <i>Nat Rev Drug Discov</i> , June 2002, pp. 457-462, Vol. 1.			
	R44	SMITH, G.E. et al. "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector," <i>Molecular and Cellular Biology</i> , December 1983, pp. 2156-2165, Vol. 3, No. 12.			
	R45	TASCON, R.E. et al. "Vaccination against tuberculosis by DNA injection," <i>Nature Medicine</i> , August 1996, pp. 888-892, Vol. 2, No. 8.			
	R46	TERPE, K. "Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems," <i>Appl Microbiol Biotechnol</i> , 2003, pp. 523-533, Vol. 60.			
	R47	THOMPSON, J.D. et al. "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice," <i>Nucleic Acids Research</i> , 1994, pp. 4673-4680, Vol. 22, No. 22.			
	R48	TUTUNCU, Z. et al. "Anti-TNF therapy for other inflammatory conditions," <i>Clin Exp Rheumatol</i> , 2002, pp. S146-S151, Vol. 20 (Suppl 28).			
	R49	VASSEROT, A.P. et al. "Optimization of protein therapeutics by directed evolution," <i>Drug Discov Today</i> , February 2003, pp. 118-126, Vol. 8, No. 3.			
	R50	VILLAIN, M. et al. "Covalent capture: a new tool for the purification of synthetic and recombinant polypeptides," <i>Chemistry and Biology</i> , 2001, pp. 673-679, Vol. 8.			
	R51	VLASAK, R. et al. "Nucleotide sequence of cloned cDNA coding for honeybee prepromelittin," <i>Eur. J. Biochem</i> , 1983, pp. 123-126, Vol. 135.			
	R52	WATT, S.M. et al. "Functionally defined CD164 epitopes are expressed on CD34 <sup>+</sup> cells throughout ontogeny but display distinct distribution patterns in adult hematopoietic and nonhematopoietic tissues," <i>Blood</i> , May 15, 2000, pp. 3113-3124, Vol. 95, No. 10.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	6	of	6	Application Number	10/565,741
				Filing Date	January 23, 2006
				First Named Inventor	Yolande Chvatchko
				Group Art Unit	1644
				Examiner Name	
				Attorney Docket Number	ARS-120

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R53	WATT, S.M. and CHAN, J.Y. "CD164-A Novel Sialomucin On CD34 <sup>+</sup> Cells," <i>Leukemia and Lymphoma</i> , 2000, pp. 1-25, Vol. 37, Nos. 1-2.	
	R54	WILSON, I.A., et al. "The Structure of an Antigenic Determinant in a Protein," <i>Cell</i> , July 1984, pp. 767-778, Vol. 37.	
	R55	WONG, T.-K. et al. "Appearance of β-lactamase activity in animal cells upon liposome-mediated gene transfer," <i>Gene</i> , 1980, pp. 87-94, Vol. 10.	
	R56	ZANNETTINO, A.C.W. et al. "The Sialomucin CD164 (MGC-24v) Is an Adhesive Glycoprotein Expressed by Human Hematopoietic Progenitors and Bone Marrow Stromal Cells That Serves as a Potent Negative Regulator of Hematopoiesis," <i>Blood</i> , October 15, 1998, pp. 2613-2628, Vol. 92, No. 8.	
	R57	ZANNETTINO, A.C.W. "CD164," <i>J Biol Regul Homeostat Agents</i> , 2001, pp. 394-396, Vol. 15.	

Examiner Signature	Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.